Micronised progesterone

As a component of menopausal hormone therapy

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Micronised progesterone (mP) was TGA approved in 2016 for use as a progestogen in menopausal hormone therapy (MHT). It has improved bioavailability when taken orally, appears to have a more favourable breast safety profile than other progestogens, is neutral with respect to cardiovascular disease risk and does not cause adverse mood effects.

Original languageEnglish
Pages (from-to)53-55
Number of pages3
JournalMedicine Today
Volume18
Issue number1
Publication statusPublished - 1 Jan 2017

Keywords

  • Menopause
  • Progesteron therapy

Cite this

@article{bd85df992580457cbdf64db709eb5d13,
title = "Micronised progesterone: As a component of menopausal hormone therapy",
abstract = "Micronised progesterone (mP) was TGA approved in 2016 for use as a progestogen in menopausal hormone therapy (MHT). It has improved bioavailability when taken orally, appears to have a more favourable breast safety profile than other progestogens, is neutral with respect to cardiovascular disease risk and does not cause adverse mood effects.",
keywords = "Menopause, Progesteron therapy",
author = "Davis, {Susan R}",
year = "2017",
month = "1",
day = "1",
language = "English",
volume = "18",
pages = "53--55",
journal = "Medicine Today",
issn = "1443-430X",
publisher = "Medicine Today",
number = "1",

}

Micronised progesterone : As a component of menopausal hormone therapy. / Davis, Susan R.

In: Medicine Today, Vol. 18, No. 1, 01.01.2017, p. 53-55.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Micronised progesterone

T2 - As a component of menopausal hormone therapy

AU - Davis, Susan R

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Micronised progesterone (mP) was TGA approved in 2016 for use as a progestogen in menopausal hormone therapy (MHT). It has improved bioavailability when taken orally, appears to have a more favourable breast safety profile than other progestogens, is neutral with respect to cardiovascular disease risk and does not cause adverse mood effects.

AB - Micronised progesterone (mP) was TGA approved in 2016 for use as a progestogen in menopausal hormone therapy (MHT). It has improved bioavailability when taken orally, appears to have a more favourable breast safety profile than other progestogens, is neutral with respect to cardiovascular disease risk and does not cause adverse mood effects.

KW - Menopause

KW - Progesteron therapy

UR - http://www.scopus.com/inward/record.url?scp=85014375411&partnerID=8YFLogxK

M3 - Review Article

VL - 18

SP - 53

EP - 55

JO - Medicine Today

JF - Medicine Today

SN - 1443-430X

IS - 1

ER -